Jul 22, 2026 04:15AM
Jul 2, 2026 08:45AM
Jul 2, 2026 06:42AM
Jun 25, 2026 06:17AM
Jun 24, 2026 04:09AM
Jun 22, 2026 12:29PM
May 5, 2026 04:20PM Exelixis (EXEL) Tops Q1 EPS by 10c, provides guidance
Apr 21, 2026 09:44AM
Feb 12, 2026 07:11AM
Feb 11, 2026 05:22AM
Feb 10, 2026 04:12PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Jan 27, 2026 07:06AM Exelixis (EXEL) PT Raised to $52 at H.C. Wainwright
Jan 14, 2026 08:56AM
Jan 14, 2026 04:48AM
Jan 12, 2026 08:28AM
Jan 12, 2026 04:05AM
Jan 8, 2026 03:36AM
Jan 5, 2026 06:19AM
Dec 18, 2025 04:29AM Exelixis (EXEL) Has Multiple Upcoming Milestones for Zanzalintinib - Citizens
Dec 11, 2025 07:42AM
Nov 17, 2025 04:12PM
Nov 5, 2025 01:55AM
Nov 4, 2025 04:27PM
Nov 4, 2025 04:17PM
Oct 21, 2025 05:33AM
Oct 21, 2025 04:09AM Citizens Reiterates Exelixis (EXEL) at Market Outperform on STELLAR-303 Franchise Potential
Oct 20, 2025 08:27AM
Oct 14, 2025 07:29AM
Oct 7, 2025 03:02PM
Sep 22, 2025 09:33AM
Sep 19, 2025 04:06AM
Sep 17, 2025 02:27AM
Aug 12, 2025 06:40AM Exelixis (EXEL) PT Lowered to $46 at H.C. Wainwright
Jul 29, 2025 09:20AM
Jul 29, 2025 09:02AM
Jul 29, 2025 08:46AM
Jul 29, 2025 04:57AM
Jul 28, 2025 04:57PM
Jul 28, 2025 04:09PM
Jul 24, 2025 05:04PM Exelixis partner Ipsen gets EU approval for neuroendocrine tumor treatment
Jul 24, 2025 04:31AM
Jul 23, 2025 02:43PM
Jul 15, 2025 09:12AM
Jun 30, 2025 06:48AM
Jun 23, 2025 10:32AM
Jun 23, 2025 10:09AM
Jun 23, 2025 10:09AM William Blair Reiterates Outperform Rating on Exelixis (EXEL), 'First pivotal success from the zanzalintinib program'
Jun 23, 2025 09:20AM

421,022 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All